The START PPOs correctly prescribed to patients were: (1) the combination of a statin with coronary, cerebral, or peripheral vascular disease (START A5) and an ACE inhibitor with systolic heart failure or coronary heart diseases (START A6), which had a small lift of 1.043 against mortality and (2) the combination of START A3 (antiplatelet therapy with coronary, cerebral, or peripheral vascular disease) (START A5 and A6) which had a similar small lift of 1.042 against mortality (Table S1). Here, ACE is linked to peripheral vascular disease.